Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Study ID
NCT06900088
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Selinexor — DRUG
    maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation

Study Details

Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study

Key Dates

Start date
Apr 25, 2025
Status verified
Dec 2024
Primary completion
Oct 30, 2025
Completion
Oct 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: patients with high-risk myeloid neoplasms after transplantation
    maintenance therapy with Selinexor combined with Azacitidine

Primary Outcome Measure

2-year recurrence free survival rate (RFS) [ Time Frame: 2 years ]

Central Contacts

Related Studies